Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors

被引:5
|
作者
Mendonca, Nikolai P. [1 ]
Kadayakkara, Deepak K. [1 ]
Forde, Inga C. [1 ]
Rudkovaskaia, Anastasiia [1 ]
Saul, Zane K. [1 ]
Lobo, David J. [1 ]
机构
[1] Bridgeport Hosp, Yale New Haven Hlth, Dept Internal Med, Bridgeport, CT USA
来源
关键词
Lymphopenia; Multiple Myeloma; Nocardia; Proteasome Inhibitors;
D O I
10.12659/AJCR.896280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Rare co-existance of disease or pathology Background: The use of proteasome inhibitors like Bortezomib to treat multiple myeloma has been associated with increased rates of opportunistic infections, including Nocardia, especially when lymphopenia is present. The prevalence or association of such infections with newer agents like Carfilzomib is not known. Case Report: A 71-year-old man with multiple myeloma presented with a 6-week history of respiratory symptoms and cyclic fevers. He was undergoing chemotherapy with Carfilzomib. Work-up revealed severe lymphopenia and a CT chest showed multiple lung nodules and a mass-like consolidation. He underwent a bronchoscopy, and respiratory cultures grew Nocardia species. He responded well to intravenous antibiotics with resolution of symptoms and CT findings. Conclusions: With the introduction of newer agents like Carfilzomib for the treatment of multiple myeloma, clinicians must maintain a high degree of suspicion for opportunistic infections to achieve early diagnosis and treatment.
引用
收藏
页码:76 / 78
页数:3
相关论文
共 50 条
  • [41] Proteasome inhibitors in the clinical setting: Benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors
    Cheriyath V.
    Jacobs B.S.
    Hussein M.A.
    Drugs in R & D, 2007, 8 (1) : 1 - 12
  • [42] Prognostic Value of the Parameters of Myeloma Bone Disease Signaling in Patients with Newly Diagnosed Multiple Myeloma Treated with Proteasome Inhibitors
    Minarik, Jiri
    Hermanova, Zuzana
    Hrbek, Jan
    Petrova, Pavla
    Flodr, Patrik
    Krhovska, Petra
    Pika, Tomas
    Bacovsky, Jaroslav
    Herman, Miroslav
    Scudla, Vlastimil
    BLOOD, 2016, 128 (22)
  • [43] Inside of multiple mechanism of adaption towards the proteasome inhibitors in multiple myeloma
    Besse, Andrej
    Besse, Lenka
    Kraus, Marianne
    Bader, Jurgen
    Novkovic, Mario
    Kryukov, Fedor
    Nemec, Pavel
    Silzle, Tobias
    Driessen, Christoph
    CANCER RESEARCH, 2016, 76
  • [44] Expression of immunoglobulin and its receptor are major determinants of multiple myeloma patient sensitivity to proteasome inhibitors
    Tuch, Brian B.
    Loehr, Andrea
    Degenhardt, Jeremiah D.
    Kwei, Kevin A.
    Lowe, Eric
    Stephenson, Kristi
    Keats, Jonathan J.
    Kirk, Christopher J.
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
    Pelon, Marta
    Krzeminski, Patryk
    Tracz-Gaszewska, Zuzanna
    Misiewicz-Krzeminska, Irena
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [46] The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
    Paradzik, Tina
    Bandini, Cecilia
    Mereu, Elisabetta
    Labrador, Maria
    Taiana, Elisa
    Amodio, Nicola
    Neri, Antonino
    Piva, Roberto
    CANCERS, 2021, 13 (06) : 1 - 34
  • [47] Impaired proteasomal capacity as the target of proteasome inhibitors in multiple myeloma
    Cenci, S
    Mezghrani, A
    Cascio, P
    Oliva, L
    Orsi, A
    Cerruti, F
    Masciarelli, S
    Mattioli, L
    Pasqualetto, E
    Sitia, R
    BONE, 2005, 36 : S215 - S216
  • [48] Proteasome inhibitors block lkaros degradation by lenalldomide in multiple myeloma
    Shi, Chang-Xin
    Kortum, Klaus Martin
    Zhu, Yuan Xiao
    Jedlowski, Patrick
    Bruins, Laura
    Braggio, Esteban
    Stewart, A. Keith
    HAEMATOLOGICA, 2015, 100 (08) : E315 - E317
  • [49] Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
    Zhou, Jianbiao
    Chng, Wee-Joo
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (09): : 303 - 306
  • [50] Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
    Kubiczkova, Lenka
    Pour, Ludek
    Sedlarikova, Lenka
    Hajek, Roman
    Sevcikova, Sabina
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (06) : 947 - 961